- Chris Seto has been appointed Chief Executive Officer, effective April 1, 2021
- Previously, Mr. Seto was responsible for overseeing the financial and operational management of Spectral Medical
- Mr. Seto has over 25 years of capital markets and financial management experience
- Mr. Seto holds a B. Comm., an MBA and a Certified Management Accountant designation
- Spectral is a Phase III company seeking U.S. FDA approval for Toraymyxin™ (“PMX”), its unique product for the treatment of patients with septic shock
- Spectral Medical (EDT) is down 3.23 per cent, trading at C$0.60 per share at 2:45 pm EST
Spectral Medical Inc. (EDT) has appointed Chris Seto as Chief Executive Officer, effective April 1, 2021.
Mr. Seto will continue to serve as the company’s Chief Financial Officer (“CFO”).
Dr. Paul Walker, the current CEO, will remain as a member of the board of directors, where he will support the leadership transition.
Previously, Mr. Seto was responsible for overseeing the financial and operational management of Spectral Medical including, finance, accounting, treasury and capital markets, as well as corporate planning and development, and investor relations.
Prior to joining Spectral Medical, Mr. Seto was the CFO of MJardin Group Inc. and GrowForce Holdings Inc.
Mr. Seto has over 25 years of capital markets and financial management experience, including senior investment banking positions with Paradigm Capital, UBS Securities and CIBC World Markets; and financial management experience in the telecom and healthcare industries with Bell Canada and Warren Shepell.
Mr. Seto holds a B. Comm. from McMaster University, an MBA from the Richard Ivey School of Business, and a Certified Management Accountant designation (C.M.A. 1999).
“I would like to thank Dr. Walker and the Board of Directors for their confidence in my ability to lead Spectral to achieve growth in product commercialization, revenues and earnings in due course.
I look forward to working with the Spectral team to continue on the exciting path we have developed for our Company under the leadership of Dr. Walker,” said Chris Seto, COO and CFO of Spectral Medical.
“Over the last year, we refined our corporate structure, including the recent appointment of Dr. John Kellum as Chief Medical Officer, which will make this transition seamless while maintaining our team’s focus on achieving our key corporate priorities.”
Dr. Walker commented,
“I am very pleased that Chris is transitioning to the Chief Executive Officer position. Since joining the company, Chris has played a key role in defining our strategy for the Dialco subsidiary. With the recent addition of Dr. John Kellum to our organization, I am confident that we are well-positioned to successfully complete the Tigris Trial and to advance our scientific and product development agenda for Spectral.”
Anthony Bihl, Chairman of Spectral, further noted,
“Chris’ transition to CEO is a reflection of his unwavering commitment and outstanding leadership. Moreover, I would like to personally express our sincere gratitude to Dr. Paul Walker, who has successfully led the organization over the last twenty years through a transition from a diagnostic focused company to a leading theranostics company focused on bringing unique commercial products to market—positioning us for long-term success.
Spectral is a Phase III company seeking U.S. FDA approval for Toraymyxin™ (“PMX”), its unique product for the treatment of patients with septic shock.
Spectral Medical (EDT) is down 3.23 per cent, trading at C$0.60 per share at 2:45 pm EST.
